

Financial Statements

Of

BMST Stem Cell Donor Registry Foundation India

(a company incorporated u/s. 8 of the Companies Act, 2013)

For the Period


01-01-2017 to 10-10-2017

BMST Stem Cell Donor Registry Foundation India

(a company incorporated u/s. 8 of the Companies Act, 2013)

CIN - U74900KA2015NPL082065

Registered Office	New Thippasandra Main Road, HAL III Stage, Bangalore - 560 075 Karnataka, India
Directors	Dr.Latha Jagannathan (Director) Mr. Prabhashankar Narayanarao Khokale (Director) Dr.Vinod Swaroop Saxena (Independent Director) Ms.Sandra Geb Mayer Bothur (Independent Director) Dr.Alexander Heinrich Schmidt (Independent Director)
Statutory Auditors	K G Acharya & Co., Chartered Accountants, No. 14, Girls School Street, Kumarapark West, Seshadripuram, Bangalore - 560 020





INDEPENDENT AUDITOR'S REPORT

To

DKMS Gemeinnützige GmbH

(Holding Company)

Germany

Report on the Financial Statements

We have audited the accompanying financial statements of **BMST Stem Cell Donor Registry Foundation India** ("the Company") for the period 01-Jan-2017 to 10-Oct-2017, which comprise the Balance Sheet as at October 10, 2017, the Statement of Income & Expenditure for the period 1st Jan 2017 to 10th Oct 2017, the Cash Flow Statement for the period then ended, and a summary of significant accounting policies and other explanatory information.

These Financial Statements have been prepared by management of the company on specific request by its Holding Company M/s. DKMS Gemeinnützige GmbH to facilitate Consolidation of its Financial Statements under the German statutes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of these financial statements that give a true and fair view of the state of affairs, results of operations and cash flows of the Company in accordance with the financial reporting provisions in accordance with the accounting principles generally accepted in India, including the applicable Accounting Standards; this includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, ("the Act"). Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts, the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 10th October, 2017, its Surplus and its cash flow for the Period 01-Jan-2017 to 10-Oct-2017.

Other Matter

The company has prepared a separate set of Financial Statements for the Financial Year 01-April-2017 to 31-March-2017 in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 on which we have issued a separate Auditor's Report to the shareholders of the company dated 28th September 2017.


Bangalore
31.01.2018

For M/s. K G Acharya & Co.,
Chartered Accountants

FRN 008019S

Suritha Jain
Partner

M. No. 227400



BMST Stem Cell Donor Registry Foundation India

(A Company incorporated Under Sec. 8 of the Companies Act, 2013)

Balance Sheet as at 10th October 2017

Particulars	Note No.	As at
		10.10.2017 (Amount in INR)
I EQUITY AND LIABILITIES		
1) Shareholders' funds		
(a) Share Capital	1	200
(b) Corpus Fund	2	1,00,000
(c) Reserves & Surplus	3	89,368
2) Share Application Money Pending Allotment	8.9	99,800
2) Current Liabilities		
(a) Other Current Liabilities	4	53,738
Total		3,43,106
II ASSETS		
1) Non Current Assets		
(a) Long-term Loans and Advances	5	3,000
2) Current Assets		
(a) Cash and Bank Balances	6	3,40,106
Total		3,43,106

Significant Accounting Policies & Other Explanatory
Information forming part of the financials statements

8

Subject to our report of even date attached

For M/s. K. G. Acharya & Co.,

Chartered Accountants

FRN. 008019S


Sunitha Jain

Partner

M.No. 227400

Bangalore

31-01-2018



For BMST Stem Cell Donor Registry Foundation India

Dr. Latha Jagannathan


Director

DIN : 00176248

Mr. Prabhashankar K N

Director

DIN : 01499577



BMST Stem Cell Donor Registry Foundation India

(A Company incorporated Under Sec. 8 of the Companies Act, 2013)

Statement of Income & Expenditure for the Period 01.01.2017 to 10.10.2017

Particulars	Note No.	From 01.01.2017 to 10.10.2017
		(Amount in INR)
I. Revenue from operations		-
II. Donations Received		2,00,000
III. Total Revenue		2,00,000
IV. Expenses:		
Other Expenses	7	1,32,520
Total expenses		1,32,520
V. Excess of Income over Expenditure	III - IV	67,480
VI. Tax Expense		-
VII. Surplus / (Deficit) for the Year	V - VI	67,480
VIII. Basic Earnings per Equity Share of Face Value Rs.10/- each		3,374

Significant Accounting Policies & Other Explanatory
Information forming part of the financial statements

8

Subject to our report of even date attached

For M/s. K. G. Acharya & Co.,
Chartered Accountants

FRN. 008019S

Sunitha Jain

Partner

M.No 227400

Bangalore

31.01.2018



For BMST Stem Cell Donor Registry Foundation India

Dr. Latha Jagannathan


Director

DIN : 00176248

Mr. Prabhashankar K N

Director

DIN : 01499577



BMST Stem Cell Donor Registry Foundation India

(A Company incorporated Under Sec. 8 of the Companies Act, 2013)

Cash Flow Statement for the Period 01.01.2017 to 10.10.2017

Particulars	10.10.2017 (Amount in INR)
A) Cash Flow From Operating Activities	
Surplus/Deficit	67,480
Operating profit before working capital changes	67,480
Adjustments for increase/decrease in- Other payables	52,188
Cash generated from operating activities	1,19,668
Taxes paid (net of refunds)	-
Net cash generated from operating activities (A)	1,19,668
B) Cash Flow From Investing activities	
Net cash applied in investing activities (B)	-
C) Cash Flow From Financing Activities	
Share Application Money	99,800
Net cash generated from financing activities (C)	99,800
D) Net increase in cash and cash equivalents (A + B + C)	2,19,468
E) Opening Cash and cash equivalents	1,20,638
F) Closing Cash and cash equivalents (D + E)	3,40,106


Significant Accounting Policies & other explanatory information forming part of the financial statements

8

Subject to our report of even date attached
For M/s. K. G. Acharya & Co.,
Chartered Accountants
FRN. 008019S


Sunitha Jain
Partner
M.No 227400

Bangalore
31.01.2018



For BMST Stem Cell Donor Registry Foundation India

Dr. Latha Jagannathan
Director
DIN : 00176248



Mr. Prabhashankar K N
Director
DIN : 01499577


Notes:

1. Cash and Cash Equivalents consist of cash on hand and balance with banks



	As at 10.10.17	As at 31.12.16
Cash on Hand	27,464	-
Balances with Bank in Current Account	3,12,642	1,20,638
Total	3,40,106	1,20,638

2. The Cash Flow Statement has been prepared under "Indirect Method" pursuant to the requirements of AS - 3 - "Cash Flow Statement" as notified under Section 133 r/w rule 7 of Companies (Accounts) Rules 2014.


Notes to Balance Sheet	
Particulars	As at 10.10.2017 (Amount in INR)
Note No. 1	
Share Capital	
Authorized Share Capital	
10,000 (10,000) Equity Shares of Rs. 10 each	1,00,000
Issued, Subscribed & Paid up	
20 (20) Equity Shares of Rs. 10 each	200
Additional Disclosures (also see note 8.6)	
(a) Reconciliation of number of shares outstanding at beginning and end of the reporting period	
Particulars	No. of Shares
At the beginning of the year	20
Add: Allotment / (Buy-Back) during the year	-
At the end of the period	20
(b) Shares held by Shareholders holding more than 5% Shares	
Particulars	No. of Shares
Dr. Latha Jagannathan	10
Mr. Prabhashankar K N for Bangalore Medical Services Trust	10
Particulars	₹
Note No. 2	
Corpus Fund	
Opening Balance	1,00,000
	1,00,000
Note No. 3	
Reserves and Surplus	
Surplus - Income & Expenditure account (*)	89,368
	89,368
(*) Surplus / (Deficit) in Income & Expenditure account	
Opening Balance	21,888
Add: Surplus / (deficit) for the Year	67,480
	89,368



Notes to Balance Sheet	
Particulars	As at 10.10.2017 (Amount in INR)
Note No. 4	
Other Current Liabilities	
Creditors for Expenses	13,664
Share Application money due for refund (also see note 8.9)	40,074
	53,738
Note No. 5	
Long-term loans and advances	
Security Deposits	3,000
	3,000
Note No. 6	
Cash and Bank Balances	
Cash and Cash Equivalents	
Cash in hand	27,464
Balances with Banks - in Current Account	3,12,642
	3,40,106



Notes Forming Part of Statement of Income & Expenditure	
Particulars	From 01.01.2017 to 10.10.2017 (Amount in INR)
Note No. 7	
Other Expenses	
Payment to Auditors -	
- as Auditors	
Rates & Taxes	29,500
Conveyance	12,100
Printing and Stationery	23,547
Office Expenses	32,907
	34,466
	1,32,520



Note No. 8

Significant Accounting Policies and Other Explanatory Information forming part of the Financial Statements for the period ended 10th October 2017 of BMST Stem Cell Donor Registry Foundation India

About the Company

BMST Stem Cell Donor Registry Foundation India was incorporated on 6th August 2015 under sec. 8 of the Companies Act 2013 with the following main objectives –



- a. To help and support people suffering from blood cancer and other diseases of the blood producing or hematopoietic system, in particular to those diseases for which an unrelated stem cell transplant is an appropriate treatment and to support such patients, directly or indirectly, including development of treatment facilities and providing guidance and advice.
- b. To set up a stem cell donor center and/or registry in India and to give people an opportunity to register as potential blood stem cell donor at public donor drives, company drives and/or through internet. To maintain a personalized database of registered potential/actual donors, including contact information, tissue characteristics as well as their medical and personal information in an anonymous format available for worldwide donor search through national/international donor registries and further to recruit, consent and advise potential blood stem cell donors in India, collecting biological samples and arranging for high resolution typing and other medical laboratory tests as well as handling/ responding requests of potential donors/patients, coordinating logistics, collection and transportation of bone marrow or blood stem cell products and monitoring short and long term health of donors post-donation.
- c. To inform public about blood cancer and other diseases of blood producing system and to promote awareness about stem cell transplantation as a mode of treatment for patients suffering from these diseases and to inform the public about the need for voluntary and unpaid stem cell donors by way of conducting publicity drives, training, awareness and advertising campaigns in particular by using print materials, internet, social media and / or radio and television.
- d. To support other non-profit organizations, in India or abroad, financially as well as non-financially, which fulfill the same or similar objects and to cooperate with other donor centers, stem cell registries, laboratories, transplant centers and collection centers as well as other organizations in the field of stem cell transplantation in order to promote these objectives. To subscribe to, become member of and co-operate with any association whether incorporated or not whose objects are similar to those contained in this memorandum. This will include organizations such as World Marrow Donor Associations and Bone Marrow Donor Worldwide.

The Company is yet to undertake the activities to accomplish its objects.

8.1 Significant accounting policies

8.1.a Basis of preparation of financial statements

The financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under the historical cost convention on accrual basis. GAAP comprises mandatory Accounting Standards as specified under Sec. 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014. Accounting policies have been consistently applied except where a newly issued Accounting Standard is initially adopted or a revision to an existing Accounting Standard requires a change in the accounting policy hitherto in use.



8.1.b Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures of contingent liabilities at the date of the financial statements and reported amounts of income and expenses during the period.

Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Difference, if any, between the actual results and estimates are recognized in the period in which the results are known / materialized.

8.1.c Cash Flow statement

Cash flows are reported using the indirect method, whereby excess of Income over Expenditure before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short term (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

8.1.d Recognition of Income and Expenditure

General Grants and Donations are recognized in the period in which they are received.

Contributions received with specific directions that they must form part of the Corpus are recognized in the Balance Sheet under Equity & Liabilities under Corpus Fund.

Other Items of Income and Expenditure are recognized on accrual basis.

8.1.e Earnings per share (EPS)

Basic EPS is computed by dividing the net profit after tax by the weighted average number of equity shares outstanding during the period.


8.1.f Income Taxes

The company was incorporated on 6th August 2015 under sec. 8 of the Companies Act 2013. The company has also been granted registration under section 12A of the Income Tax Act, 1961 for claiming exemption under section 11 & 12 of said Act. Hence, no provision for income tax has been made and Deferred Tax Liability / Asset has not been determined.

8.2 Earnings / Expenditure incurred in Foreign Currency

(Amount in ₹)	
Particulars	Y.E. 10.10.2017
a) Expenditure incurred in Foreign Currency - Foreign Travel and accommodation	39,881
b) Income in Foreign Currency	Nil

1-9. 7



8.3 There were no employees on rolls of the company. As such the company has not made any provision arising as per the "The Payment of Gratuity Act".

8.4 Disclosure in respect of Related Parties transactions as per Accounting Standard 18 – Related Party Disclosure for the period ended 10th October 2017 is as given below:

(a) List of related parties

- a. over which control exists – Nil
- b. Who exercise control –

Relationship	Name of the Related Party
Key Management Personnel (KMP)	• Dr. Latha Jagannathan
Enterprise which exercises significant influence	• Bangalore Medical Services Trust Represented by Mr. Prabhashankar K N

(b) Names of the Related Parties with whom transactions were carried out during the period and description of relationship.


Relationship	Name of the Related Party
Enterprise which exercises significant influence	• Bangalore Medical Services Trust Represented by Mr. Prabhashankar K N

(c) Summary of Transactions with the Related Parties –

Particulars	(Amount in ₹)
	Enterprise which exercises significant influence
Share Application Money Received	24,800

(d) Balances payable

Particulars	(Amount in ₹)	
	Enterprise which exercises significant influence	KMP
	10.10.2017	10.10.2017
Contribution to Equity Share Capital	100	100
Share Application Money pending Allotment	24,800	-



8.5 The Company is a Small and Medium Sized Company (SMC) as defined in the General Instructions in respect of Accounting Standards specified under Sec. 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.

8.6 Rights and Restrictions attached to Equity Shares

The Company has one class of equity shares having a par value of ₹.10/- each. Each shareholder is eligible for one vote per share held. As per the provisions of Section 8 of the Companies Act, 2013 distribution of dividends to shareholders is prohibited. Further the shareholders are not entitled to the assets of the company on liquidation.

8.7 Basic Earnings per Share computed in accordance with AS 20: Earnings per Share:

Particulars	10.10.2017
Surplus/(Deficit) after tax as per Accounts	67,480
Weighted average number of shares outstanding	20
Basic EPS (₹)	3,374

8.8 Dues to micro & small enterprises

The Company has no dues to micro and small enterprises during the period ended 10th October 2017.

8.9 Disclosure for Share Application Money Pending Allotment

9,980 No's Equity Shares of Face Value Rs. 10 were issued at par on October 10, 2017 against the Share application money pending allotment. The Authorised Capital of the Company is Rs. 10 Lacs and the Paid up Capital post the said allotment was Rs. 1 Lacs. The company has received excess share application money which had remained outstanding and was repaid on 28th December 2017.

8.10 These Financial statements for the period 01.01.2017 to 10.10.2017 have been prepared on specific request by the Holding Company M/s. DKMS Gemeinnützige GmbH to facilitate Consolidation of its Financial Statements under the German statutes and the same accounting policies as are adopted for Annual Financial Statements have been applied. Data regarding Audited Comparative Previous year figures are not available and are therefore not presented.

8.11 Paises have been rounded off to nearest rupee and due to this rounding off, the numbers presented throughout the document may not add up precisely to the totals and percentages may not precisely reflect the absolute figures.

Subject to our report of even date
For M/s. K G Acharya & Co.,
Chartered Accountants
FRN 00801954

Sunitha Jain
Partner
M. No. 227400



Bangalore
31.01.2018

For BMST Stem Cell Donor Registry Foundation India

Dr. Latha Jagannathan
Director
DIN :00176248

Mr. Prabhaskar K N
Director
DIN :01499577

